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Background. Inﬂammatory bowel diseases (IBD) occurred in genetically predisposed people exposed to environmental triggers.
Diet has long been suspected to contribute to the development of IBD. Supplementation with n-3 polyunsaturated fatty acids
(PUFA) protects against intestinal inﬂammation in rodent models while clinical trials showed no beneﬁts. We hypothesized that
intervention timing is crucial and dietary fatty acid pattern may inﬂuence intestinal environment to modify inﬂammation
genesis. The aim of this study was to evaluate the dietary eﬀect of PUFA composition on intestinal inﬂammation. Methods.
Animals received diet varying in their PUFA composition for four weeks before TNBS-induced colitis. Colon inﬂammatory
markers and gut barrier function parameters were assessed. Inﬂammatory pathway PCR arrays were determined. Results. n-3
diet signiﬁcantly decreased colon iNOS, COX-2 expression, IL-6 production, and LTB4 production but tended to decrease colon
TNFα production (P = 0 0617) compared to control diet. Tight junction protein (claudin-1, occludin) expressions and MUC2
and TFF3 mRNA levels were not diﬀerent among groups. n-9 diet also decreased colon IL-6 production (P < 0 05). Conclusions.
Dietary n-3 PUFA inﬂuence colitis development by attenuating inﬂammatory markers. Further research is required to better
deﬁne dietary advice with a scientiﬁc rationale.
1. Introduction
Inﬂammatory bowel diseases (IBD) aﬀects genetically
predisposed people exposed to environmental triggers [1].
Amongst environmental factors, dietary habits have long
been suspected to contribute to the development of IBD [2].
IBD patients often considered diet as a potential trigger for
initiating the disease or causing a relapse [3], and this concept
led to exclusion diets especially in children [4].
An increased incidence of IBD has been associated with
diets high in animal protein. Indeed, association between
dietary pattern (fat/protein) and Crohn’s disease (CD) risk
was found in a study from Japan [5] while increased
consumption of animal protein has been associated with
higher IBD risk in a study from France [6]. A systematic
review demonstrated that this Western dietary pattern (high
fat, high n-6 polyunsaturated fatty acids (PUFA), and high
meat) is associated with an increased IBD risk [7]. More
recently, a study was conducted in 103 IBD patients using
food frequency questionnaire over 1 year and the authors
found a positive association between meat intake and disease
relapse [8]. Similarly, Western diet had a deleterious impact
on gut barrier function and dysbiosis in IBD murine
models [9].
While n-3 and n-6 PUFA are essential in human nutri-
tion, a Western diet is characterized by an unbalanced ratio
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of both types of PUFA (n-3/n-6 ratio). Indeed, linoleic acid
(LA, n-6 PUFA) consumption hasmarkedly increased (3-fold
throughout the 20th century) [10]. Numerous epidemiologi-
cal studies highlighted the role of dietary intake of monoun-
saturated fatty acids (MUFA) or PUFA in ulcerative colitis
(UC) development. Higher intake of LA is associated with
an increased risk of UC [11], while docosahexaenoic acid
(DHA) (n-3 PUFA) [12] or oleic acid (n-9 MUFA) [13, 14]
consumption is beneﬁcial. Ananthakrishnan et al. found that
greater ﬁsh intake was associated with lower risk of CD [15].
We and others demonstrated an anti-inﬂammatory
eﬀect of n-3 polyunsaturated fatty acids in rodent IBD
models [16–21] while clinical trials failed [22]. We hypothe-
sized that intervention timing is crucial and dietary fatty acid
pattern may inﬂuence intestinal environment to modify
inﬂammation genesis [23].
The aim of the study was to investigate the dietary
inﬂuence of fatty acid composition before the onset of intes-
tinal inﬂammation by administration of 2,4,6-trinitroben-
zene sulfonic acid (TNBS). For this purpose, rats were fed
with diets varying in n-3/n-6/n-9 ratio to reproduce dietary
pattern from a pragmatic to a Western diet.
2. Materials and Methods
2.1. Animals and Study Design. Young Sprague-Dawley male
rats weighing 75–100 g were purchased from Janvier (Le
Genest St. Isle, France) and allowed to access food and water
ad libitum. After 1 week acclimatization, 50 rats were ran-
domly divided into 5 experimental groups; the control
(CTRL) group was fed with control diet and received the
vehicle, while colitic groups including TNBS, n-3, n-6, and
n-9 groups were fed with control diet, n-3 diet, n-6 diet,
and n-9 diet, respectively, and received TNBS for the colitis
induction. Weight changes throughout the study were mon-
itored every day. After 4 weeks of experimental diets (day 28
to day 1), the rats underwent 24 hours food deprivation prior
to the TNBS or vehicle administration. During the colitis
induction (day 0 to 2), rats were provided control diet. The
overview of experimental design is illustrated in Figure 1(a).
All animal handling and treatment procedures were per-
formed in accordance with both French national regulations
and European Union regulations (Oﬃcial Journal of the
European Community L 358, 18/12/1986) and RML is autho-
rized to use this animal protocol by the French government
(Authorization n°76-106).
2.2. Diets. Four types of isocaloric and isolipidic experimental
diets were prepared with several fatty acid proportions:
(i) The normal diet matched a balanced diet with a
n-3/n-6/n-9 ratio equal to 1 : 4 : 16 as a fat ratio
recommended by dietary guidelines and described
as a well-balanced diet in the literature [24]. The
control diet was given to CTRL and TNBS groups.
The recommended dietary n-6/n-3 ratio is about 4
in human nutrition which is comparable to the
control diet in this study.
(ii) n-3 diet had a n-3/n-6/n-9 ratio equal to 1 : 1 : 4. We
chose a n-3/n-6 ratio equal to 1 : 1 because this ratio
was a target by dietary advice in a Japanese clinical
trial for IBD patients [25]. In addition, a n-3/n-6
ratio is commonly used in experimental studies
investigating the eﬀect of n-3 therapy [24].
(iii) n-6 diet ﬁtted the Western diet with a n-3/n-6/n-9
ratio at 1 : 16 : 16. The dietary n-6/n-3 ratio is about
15 in human Western diets [26], and this ratio is
useful to underline the imbalance that characterizes
Western diets.
(iv) n-9 diet had a similar n-3/n-6 ratio to CTRL diet but
is enriched in n-9MUFA. This n-3/n-9 ratio equal to
1 : 24 is comparable to the ratio observed in people
following the Mediterranean diet [26].
Detailed diet composition is shown in Table 1.
2.3. Induction of Colitis. Administration of TNBS (Sigma-
Aldrich Company, Saint-Quentin-Fallavier, France) was
employed for colitis induction as previously described [16]
in TNBS, n-3, n-6, and n-9 groups (colitic groups). The rats
were sacriﬁced using anesthetic reagents (ketamine and
xylazine) at day 2 for further analyses.
2.4. Western Blot. PBS, protease inhibitor cocktail, and
phosphatase inhibitor cocktail were purchased from Sigma-
Aldrich (Saint-Quentin-Fallavier, France). The 4–12%
NuPAGE gels and SeeBlue multicolored standard were
obtained from Invitrogen (Cergy-Pontoise, France). Frozen
colon samples were homogenized in PBS with 0.1% protease
inhibitor cocktail and 1% phosphatase inhibitor cocktail.
Homogenates were centrifuged (12,000g, 15min, 4°C) and
the supernatants were collected. Protein concentration was
determined following Bradford’s colorimetric method.
Aliquots of supernatants containing equal amounts of pro-
tein (30μg) were separated on 4–12% NuPAGE and then
transferred to a nitrocellulose membrane (Hybond, GE
Healthcare, UK). The mouse monoclonal antibody anti-
PPARγ (sc-7273), the goat polyclonal anti-COX-2 (sc-
1747), the mouse anti-iNOS (sc-7271), the rabbit polyclonal
anti-HNF-4 (sc-8987), and the HRP-conjugated secondary
antibodies were obtained from Santa Cruz Biotechnology
(Tebu, Le Perray-en-Yvelines, France). The rabbit anti-
claudin-1 and the mouse anti-occludin were, respectively,
obtained from Life technology and Invitrogen. After
blocking, membranes were incubated with speciﬁc primary
antibodies at the dilution of 1 : 100 (iNOS), 1 : 500 (COX-2,
HNF-4, and PPARγ), and 1 : 1000 (claudin-1, occludin. After
three washes, membranes were then incubated with the
secondary HRP-linked anti-goat IgG (for COX-2), anti-
rabbit IgG (for HNF-4, claudin-1), and anti-mouse IgG (for
iNOS, PPARγ, and occludin) antibodies. The enhanced
chemiluminescence light-detecting kit (GE Healthcare,
USA) was utilized for immunodetection. Densitometric data
were measured following normalization to the housekeeping
protein (β-actin) by a Scientiﬁc Imaging Systems (Image
QuantTL, GE Healthcare).
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2.5. RNA Isolation and Gene Expression Analyses. Colon
samples were frozen in liquid nitrogen and stored at −80°C
before RNA preparation. Total RNA was isolated from rat
colon specimens using a commercial RNA puriﬁcation kit
(SV total RNA isolation kit, Promega, Madison, WI) and
mRNA expression of Muc2 (primer sequences F: CCTTGC
TCTGCCATACCCGT, R: ACACTGGTCCTCTCCTCCCT)
and TFF-3 (F: TAACCCTGCTGCTGGTCCTG, R: GTTT
GAAGCACCAGGGCACA), and the internal control
(GAPDH) was measured by qRT-PCR. Furthermore, gene
expressions in Toll-like receptor signaling pathway were
determined by real-time PCR array according to themanufac-
turer’s protocol (PAMM-0018ZD, SA Biosciences, Frederick,
MD) on CFX96 thermocycler (Bio-Rad, Hercules, CA). Data
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Figure 1: Experimental design and clinical parameters in rats receiving diets varying in their unsaturated fatty acid composition followed by
TNBS-induced colitis. (a) Experimental design. Rats received diets varying in their PUFA composition for four weeks before colitis induction
at day 0. Rats were killed at day 2. (b) Body weight at day 2. (c) Body weight follow-up from day 28 to day 2. ∗∗ means P < 0 01 versus all
colitis groups (TNBS, n-3, n-6, and n-9).
Table 1: Fatty acid composition of the experimental diets.
CTRL n-3 diet n-6 diet n-9 diet
Total fat (g/1000 g of diet) 49.7 49.4 49.7 49.8
Saturated fat (g) 10.2 9.9 9.3 9.6
MUFA (g) 29.8 26.2 20.1 32.8
PUFA (g) 9.8 13.3 20.3 7.4
n-6 fatty acids (g) 7.9 7.3 19.1 6.1
n-3 fatty acids (g) 1.8 6.1 1.2 1.3
n-9 fatty acids (g) 29.3 25.8 19.8 32.2
n-3/n-6/n-9 ratio 1 : 4:16 1:1 : 4 1 : 16:16 1:4:24
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are expressed in fold regulation. The fold change (fold diﬀer-
ence) is calculatedby the equation2(−ΔΔCT). For the fold reg-
ulation, the software transforms fold change values less than 1
(meaning that the gene is downregulated) by returning the
negative inverse.
2.6. Colon Cytokines and LTB4 Production. Concentrations
of TNFα, IL-1β, and LTB4 in the colon homogenates were
detected by ELISA (R&D Systems, Lille, France) following
the manufacturer’s instructions.
2.7. Proteolytic Pathway Activities. The evaluation of proteo-
lytic activities (caspase-like and chymotrypsin-like) was per-
formed by spectroﬂuorometric microtiter plate ﬂuorometer
(Mithras LB 940, Berthold Technologies) using ﬂuorogenic
proteasome substrate in the presence or absence of speciﬁc
proteasome inhibitors as previously described [27].
2.8. Statistical Analysis. Statistical comparisons were per-
formed using GraphPadPrism 5. Data are expressed as
mean± SEM. Body weight changes and food intake were
analyzed with 2-way ANOVA for repeated measures with
Tukey’s post hoc tests. All the other variables were analyzed
by one-way ANOVA with Bonferroni post hoc test or
Kruskal-Wallis test as appropriate. Diﬀerences were consid-
ered signiﬁcant at P < 0 05.
3. Results
3.1. TNBS-Induced Colitis Decreased Body Weight. Colitic
groups had a lower body weight compared to control rats
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Figure 2: Inﬂammatory markers in rats receiving diets varying in their unsaturated fatty acid composition for 4 weeks followed by
TNBS-induced colitis. (a) Colon/weight length at day 2. (b) Colon iNOS expression with a representative gel at day 2. (c) Colon IL-
6 and (d) TNFα production. 5-Aminosalicylic acid (5-ASA) is used a positive anti-inﬂammatory control. Data from colitic rats were
compared by 1-way ANOVA followed by Tukey posttests. ∗∗ means P < 0 01 versus CTRL, ∗∗∗ means P < 0 001 versus CTRL,
and ∗ means P < 0 05 versus TNBS.
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(P < 0 01) at day 2 but there is no diﬀerence among colitic
groups (Figure 1(b)).
3.2. TNBS-Induced Colitis Increased Inﬂammatory Markers.
Colon weight/length ratio was increased in colitic rats
compared to control group (P < 0 01 for TNBS and n-3,
P < 0 001 for n-6 and n-9, Figure 2(a)) without signiﬁcant
diﬀerences among colitic groups (Figure 2(a)). Colon
iNOS was signiﬁcantly higher in colitic groups compared
to control group (P = 0 0141, Figure 2(b)).
3.3. n-3 Diet Decreased Colon Inﬂammatory Markers.Among
colitis groups, n-3 group had a lower colon iNOS compared
to TNBS group (P < 0 05, Figure 2(b)). Colon IL-6 produc-
tion was signiﬁcantly lower in n-3 and n-6 groups compared
to TNBS group (P < 0 05 for both, Figure 2(c)) while colon
TNFα production did not signiﬁcantly diﬀer among colitis
groups (Figure 2(d)) but tend to decrease in n-3 group
compared to TNBS group (P = 0 0617). Transcription factors
HNF-4α and PPARγ expressions were not diﬀerent among
groups (data not shown).
3.4. n-3 Diet Decreased COX-2 Expression and LTB4
Production in the Colon. Among colitis groups, n-3 group
had a lower colon COX-2 expression compared to TNBS
group (P < 0 001, Figure 3(a)). In addition, colon LTB4 pro-
duction was lower in the n-3 group compared to TNBS group
(P < 0 05, Figure 3(b)).
3.4.1. Gut Barrier Function Was Not Aﬀected by Dietary
Treatments. Tight junction proteins claudin-1 and occludin
were not diﬀerent among groups (P = 0 4750 and P = 0 8553,
resp., Figures 4(a) and 4(b)). TFF3 mRNA levels were not
diﬀerent among groups (P = 0 3729, Figure 4(c)). MUC2
mRNA levels were not diﬀerent among groups (1-way
ANOVA, P = 0 0381, posttests P > 0 05, Figure 4(d)).
3.5. Colitis or Dietary PUFA Did Not Modify Proteasome
Activity. Chymotrypsin and trypsin-like activities were not
diﬀerent among colitic groups (P = 0 3510 and P = 0 0651,
resp., data not shown).
3.6. Dietary Modulation of Inﬂammatory Gene Expression.
In colitis groups, n-3 diet upregulated IL-1A, TLR-2, and
MA2K3 genes while n-9 diet upregulated TLR-4 genes
(P = 0 044, P = 0 013, and P = 0 021, resp., Table 2). n-6
upregulated HMGB1 (P = 0 042) without aﬀecting TLR
pathways (P > 0 05, Table 2).
4. Discussion
Numerous experimental studies found anti-inﬂammatory
eﬀects of n-3 PUFA in intestinal inﬂammation while ran-
domized clinical trials failed to demonstrate eﬃcacy [2, 23].
We previously hypothesized that the discrepancy between
clinical trials and experimental studies could result from the
timing of the intervention [23]. In our previous studies in
colitis models [16–19], we tested nutritional intervention
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Figure 3: Eicosanoid pathway in rats varying in their unsaturated fatty acid composition for 4 weeks followed by TNBS-induced colitis. (a)
Colon cyclooxygenase-2 (COX-2) expression with a representative gel and (b) colon LTB4 production at day 2. 5-Aminosalicylic acid
(5-ASA) is used a positive anti-inﬂammatory control. Data from colitic rats were compared by 1-way ANOVA followed by Tukey posttests.
∗ means P < 0 05 versus TNBS, ∗∗∗ means P < 0 001 versus TNBS, and $ means P < 0 05 versus n-3.
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with n-3 PUFA in a curative manner. We now speculated
that nutritional intervention with fatty acid should be
preventive as reﬂected in the epidemiological studies. In
epidemiological studies, dietary intake of PUFA modiﬁes
IBD risk, and identiﬁcation of their potential mechanisms is
now required. To this purpose, we fed rats for four weeks
with diets diﬀering in their PUFA composition before the
onset of colitis.
In the present study, n-3 diet downregulated colon iNOS
expression (Figure 2(a)) in rats with TNBS-induced colitis
similar to previous studies performed by us [16, 19] or others
[21]. Indeed, n-3 PUFA can regulate oxidative stress.
Camuesco et al. found that olive oil enriched with ﬁsh oil
decreased oxidative activity by restoring glutathione concen-
tration and reducing iNOS expression in the colon of rats
[21]. Dietary n-3 PUFA exerted anti-inﬂammatory proper-
ties. Indeed, n-3 diet decreased colon COX-2 and colon
LTB4 production (Figure 3). This result is in accordance with
our previous studies showing an inhibitory eﬀect of nutri-
tional intervention with n-3 PUFA on COX-2 and LTB4
[16, 19]. Similarly, it has been shown that antagonizing
arachidonic acid-derived eicosanoids reduced inﬂammation
and colitis severity in mice [28]. In addition, alteration of
eicosanoids is one of the PUFA main mechanisms [29]. In
the present study, n-3 diet also downregulated colon proin-
ﬂammatory cytokines such as IL-6 (Figure 2(c)) and tend to
decrease TNFα production.
In the present study, IL-1A gene expression was upregu-
lated by n-3 diet (Table 2). This result is in accordance with
an in vitro study showing that EPA treatment increased
IL-1A secretion in human keratinocytes [30]. In our study,
we observed a signiﬁcant decreased IL-6 production
(Figure 2(c)) while IL-6 gene expression did not diﬀer
(Table 2). The discrepancy between gene expression and
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Figure 4: Gut barrier parameters in rats receiving diets varying in their unsaturated fatty acid composition for 4 weeks followed by TNBS-
induced colitis. (a) Colon claudin-1 expression, (b) occludin expression, (c) trefoil factor 3 (TFF3) mRNA level, and (d) MUC2mRNA level at
day 2. (e) Representative gel of colon claudin-1 and occludin expression. 5-Aminosalicylic acid (5-ASA) is used a positive anti-inﬂammatory
control. Data from colitic rats were compared by 1-way ANOVA followed by Tukey posttests.
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protein concentration is a frequent ﬁnding in the literature.
In a previous study, we observed that TNBS administration
led to a 60% increase of TNFα production, while a 12-fold
increase of gene expression was observed [16]. Studies that
have tested correlations between gene expression and protein
levels have found that mRNA and protein abundances are
diﬀerentially expressed, suggesting a frequent posttranscrip-
tional regulation of gene expression [31].
Dietary n-3 PUFA increased TLR2 gene compared to
control diet while n-9 diet increased TLR4 gene (Table 2).
In the literature, the inhibitory eﬀect of n-3 PUFA on TLR2
is controversial. TLR2 protein expression was downregulated
by EPA in mouse adipose stem cells [32] while a study
investigating the eﬀect of a range of saturated and unsatu-
rated fats on TLR2 and TLR4 activation found no eﬀect
[33]. The investigators of this study did not ﬁnd any eﬀect
on DHA, EPA, or oleic acid to activate TLR2 and TLR4 in
HEK-Blue cells [33]. Nevertheless, these fatty acids were
able to downregulate cytokine production such as TNFα,
IL-6, and MCP-1 secretion in human adipose tissue and
adipocyte cultures [33]. We studied dietary eﬀects on
TLR expression but we did not explore their eﬀects on
the intestinal microbiota. It has been demonstrated that
ﬁsh oil is able to attenuate n-6 PUFA-induced dysbiosis
in a colitis model [34].
Dietary n-6 increased gene expression of high-mobility
group box 1 (HMGB1, Table 2). An increased of colon
HMGB1 by dietary n-6 PUFAwas observed in rats with colon
cancer [35]. HMGB1 can activatemultiple signaling pathways
such asTLRbutwedidnot observe any increase inTLR signal-
ing by n-6 diet. Other signaling pathways such as receptor for
advanced glycation end products (RAGE) signaling may be
involved [36]. Indeed, increased RAGE via dietary n-6 has
been reported in experimental colon cancer models [37].
Except for il-1a, MAP2k3, and TLR genes, we observed
only modest eﬀect of n-3 diet in inﬂammatory gene expres-
sion. Contrary to other studies, we aimed to evaluate a dietary
eﬀect on n-3 PUFA before inﬂammation genesis while
numerous studies are interested in a pharmacological eﬀect
of n-3 PUFA in a curative manner [21, 38]. Numerous stud-
ies have used long chain n-3 PUFA [39] while the experimen-
tal diets used in the present study did not contain any long
chain PUFA; these diets cannot directly reproduce a typical
omnivore human diet. Route of administration is also a cru-
cial point, and we used diets varying in their unsaturated fatty
acid composition while n-3 PUFA are often administered by
Table 2: Inﬂammation pathway PCR array in rats receiving diets varying in their unsaturated fatty acid composition followed by TNBS-
induced colitis. Colon RNA from rats receiving diets varying in their unsaturated fatty acid composition before the onset of TNBS-
induced colitis. The results were compared to rats receiving TNBS with a control diet. Data in bold are signiﬁcantly diﬀerent from TNBS rats.
n-3 diet n-6 diet n-9 diet
Fold regulation P value Fold regulation P value Fold regulation P value
Il1a 2.29 0.044 1.33 0.224 1.50 0.157
Il1b 1.60 0.125 1.09 0.776 −1.03 0.879
Il12a −1.64 0.113 −1.12 0.532 −1.41 0.226
Il6 1.54 0.363 −2.76 0.219 −1.10 0.656
TNF 1.40 0.138 1.32 0.260 1.24 0.393
Ifng 1.06 0.417 2.30 0.124 1.78 0.183
Il10 1.49 0.378 −1.36 0.793 1.16 0.776
Il1r1 1.39 0.205 1.26 0.446 1.11 0.864
Hmgb1 1.09 0.492 1.52 0.042 1.02 0.851
Map2k3 1.65 0.021 1.36 0.117 1.2 0.278
Il2 −1.27 0.904 4.23 0.258 3.13 0.275
Clec4e 1.46 0.372 −2.13 0.184 −1.37 0.724
Lta −1.04 0.572 −2.44 0.351 −1.09 0.952
Cd86 −1.11 0.569 −1.12 0.778 −1.52 0.163
Fos −1.05 0.345 −1.3 0.379 −1.32 0.214
Irf1 −1.32 0.451 1.08 0.988 1.02 0.693
Jun −1.37 0.340 1.09 0.762 −1.34 0.158
Tlr1 1.23 0.419 −1.05 0.803 1.06 0.654
Tlr2 1.73 0.013 1.18 0.320 1.16 0.371
Tlr3 −1.38 0.320 1.25 0.659 1.11 0.846
Tlr4 1.49 0.140 1.34 0.251 2.01 0.005
Tlr5 −1.09 0.805 1.18 0.815 1.49 0.758
Tlr6 1.26 0.381 1.02 0.855 1.05 0.960
Tlr7 −1.37 0.397 −1.44 0.207 −1.29 0.299
Tlr9 −1.24 0.802 −1.18 0.877 −1.47 0.285
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gavage. These experimental design discrepancies may explain
our eﬀects on inﬂammatory gene expression.
Fatty acids are endogenous ligands for HNF-4α [40], and
the role of HNF-4α in the intestinal inﬂammatory homeosta-
sis has been demonstrated in mice with the intestinal epithe-
lial deleted HNF-4α [41]. We hypothesized that dietary
PUFA can regulate HNF-4 but we did not observe any mod-
iﬁcations of colon HNF-4α expression among groups. Simi-
larly, nuclear receptor PPARγ can be activated by PUFA
and is a regulator of intestinal inﬂammation [42, 43], but its
expression is not diﬀerent among groups.
Dietary PUFA did not aﬀect barrier function in our
study. We investigated tight junction proteins, MUC2 and
TFF3 mRNA levels, and we did not ﬁnd any signiﬁcant eﬀect
among groups (Figure 4). Some studies found a protective
eﬀect of n-3 PUFA on barrier function. Hudert et al. have
used transgenic mice carrying the C. elegans fat-1 gene
encoding an n-3 fatty acid desaturase that converts n-6 to
n-3 fatty acids and they induced DSS colitis in these mice
[44]. They found that fat-1 mice were protected from colitis
induction compared to wild-type mice with decreased
inﬂammatory markers [44]. They also found that fat-1 mice
exhibited an increased production of protective markers such
as TFF3 [44]. Fish oil supplementation in rats with TNBS-
induced colitis also increased the number of goblet cell with
mature mucin granules [38]. Nevertheless, our experimental
design is diﬀerent from these studies. Indeed, we investigated
the eﬀect of PUFA at a dietary dose while the previous studies
investigated PUFA as immunonutrients.
In the present study, n-3 diet group which showed
n-3/n-6 ratio equals to 1 attenuated inﬂammatory markers
in the colon. This preventive approach has been already
tested in small clinical trials. In a Japanese study, the eﬃcacy
of n-3 diet therapy in IBD patients has been already evaluated
[25]. The authors of this study combined a double nutritional
approach to achieve a n-3/n-6 ratio of 1 for their patients by
dietary advice and nutritional supplementation [25]. Their
patients were prohibited from consuming the main source
of n-6 PUFA consumption such as vegetable oils or dressings.
They also provided a n-3 PUFA food exchange table to priv-
ilege and n-3 supplementation [25]. The authors of this study
found a higher n-3/n-6 ratio in the remission group [25]. In a
Norwegian study, they evaluated the eﬀect of 600 g of salmon
consumption per week for 8 weeks in 12 active UC patients
and they found decreased clinical inﬂammatory index [45].
A proof of concept study is now required to evaluate n-3
PUFA in a preventive manner. As we cannot directly tar-
get IBD physiopathology with a nutritional therapy before
the IBD diagnosis, we may ﬁrst evaluate n-3 therapy in
CD postoperative patients. Indeed, postoperative phase is
considered as a perfect window to evaluate predisposing
factors to IBD recurrence.
Similarly, in a recent epidemiological study, women with
a prudent diet (characterized by greater intake of fruits,
vegetables, and ﬁsh) had a lower CD risk [15]. In addition,
greater intake of ﬁsh (P trend= 0.01) has been speciﬁcally
associated with lower risk of CD [15].
In conclusion, prudent diet with a high n-3/n-6 ratio
may contribute to partially limit colitis genesis. Further
research will be mandatory to determine mechanisms
underlying dietary eﬀects to better deﬁne dietetic advice
with a scientiﬁc rationale.
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